Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Rating of “Moderate Buy” by Brokerages

Regulus Therapeutics Inc. (NASDAQ:RGLS) has received a consensus rating of “Moderate Buy” from the five ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $7.25.

RGLS has been the topic of several recent analyst reports. Wells Fargo & Company lifted their target price on Regulus Therapeutics from $2.00 to $3.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 13th. Leerink Partnrs reissued an “outperform” rating on shares of Regulus Therapeutics in a research note on Monday, March 18th. StockNews.com began coverage on Regulus Therapeutics in a research note on Monday. They issued a “hold” rating on the stock. SVB Leerink began coverage on Regulus Therapeutics in a research note on Monday, March 18th. They issued an “outperform” rating and a $6.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Regulus Therapeutics in a research note on Monday, March 25th.

Regulus Therapeutics Trading Up 6.1 %

RGLS stock opened at $2.78 on Friday. The business’s 50-day moving average price is $2.00 and its two-hundred day moving average price is $1.55. The firm has a market cap of $181.98 million, a PE ratio of -1.75 and a beta of 1.57. Regulus Therapeutics has a 1-year low of $0.88 and a 1-year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, hitting the consensus estimate of ($0.40). On average, analysts forecast that Regulus Therapeutics will post -0.52 earnings per share for the current year.

Institutional Trading of Regulus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RGLS. Vanguard Group Inc. increased its position in shares of Regulus Therapeutics by 21.4% in the first quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock valued at $1,096,000 after acquiring an additional 648,121 shares during the last quarter. Federated Hermes Inc. acquired a new stake in shares of Regulus Therapeutics in the first quarter valued at about $8,656,000. Northern Trust Corp increased its position in shares of Regulus Therapeutics by 42.9% in the first quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 50,518 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Regulus Therapeutics by 498.2% in the first quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 111,100 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at about $54,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.